Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:58:24.727Z.
Consensus retrieved: 2026-10-06T15:42:10.937Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:58:24.727Z.
Quote observation: 2026-10-06T18:55:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd9bff75293b0061b415f76424971e71050022ba1ca13a61eeb09eda3fdb1614
Forward PE Ratio (N/A) = Dated Quote Price ($30.78) / Consensus Forward EPS ($-4.04)
FORWARD PE RATIO
N/A
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.47B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.47B | N/A |
| GH Research PLC (GHRS)vs › | $1.47B | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A |
| Certara, Inc. (CERT)vs › | $1.45B | 27.45 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 10.47 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 17.52 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 50.67 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.42B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $30.78, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.04 | $-4.46 – $-3.62 | 9 | n/m |
| 2027-12-31 | $-4.86 | $-6.72 – $-3.23 | 9 | n/m |
| 2028-12-31 | $-5.52 | $-8.56 – $-4.08 | 10 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
